4.6 Article

Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea

期刊

出版社

ELSEVIER TAIWAN
DOI: 10.1016/j.jmii.2021.11.007

关键词

Multidrug resistant tuberculosis; Nationwide study; Prescription patterns; Time series; Tuberculosis

资金

  1. Korea Health Technology R&D Project through the Korea Health Industry Development Institute
  2. Ministry of Food and Drug Safety, South Korea in 2021-2025 [21153MFDS607]
  3. Ministry of Health and Welfare, South Korea [HI19C1233]

向作者/读者索取更多资源

This study investigated the changes in prescription patterns of anti-TB drugs for patients with TB and MDR-TB in South Korea before and after the release of the national guidelines. The results showed that the prescription patterns aligned well with the WHO's treatment guidelines and domestic guidelines in South Korea.
Background/Purpose(s): The World Health Organization (WHO) released treatment guidelines for multidrug resistant tuberculosis (MDR-TB) in 2008, with subsequent revisions in 2011; Korea disseminated corresponding guidelines in 2011 and 2014, respectively. Thus, we aimed to investigate the temporal trends of and the updated guideline's impact on the pre-scription patterns of anti-TB drugs.Methods: We conducted a time-series study using Korea's nationwide healthcare database (2007-2015), where patients with TB or MDR-TB were included. Only anti-TB drugs prescribed during the intensive phase of treatment for TB (two months) or MDR-TB (eight months) were assessed. We estimated the annual utilization of TB treatment regimens and the relative dif-ference (RD) in the proportion of MDR-TB treatment medications between the following pe-riods: before the first Korean guideline (June 2008 to March 2011); between the first and revised guidelines (April 2011 to July 2014); after the revised guideline (August 2014 to December 2015). Results: Of 3523 TB (mean age 54.1 years; male 56.8%) patients, treatment regimens for TB complied with guideline recommendations as >80% of patients received either quadruple (mean 66.8%) or triple (14.5%) therapy of first-line anti-TB drugs. Following the WHO's guide-line update, prescription patterns changed accordingly among 111 MDR-TB (mean age 46.0 years; male 67.6%) patients, as use of pyrazinamide (RD +20.3%) and prothionamide (+11.5%) increased (recommended to be compulsory), and streptomycin (-43.1%) decreased (ototoxicity risks).Conclusions: Anti-TB drug prescription patterns for both TB and MDR-TB well reflected WHO's treatment guideline as well as corresponding domestic guidelines of South Korea.Copyright (c) 2021, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据